160-OR: Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 160-OR
Author(s):  
ANDREAS ANDERSEN ◽  
PETER G. JØRGENSEN ◽  
JONATAN I. BAGGER ◽  
MARIA POMPEA ANTONIA BALDASSARRE ◽  
MIKKEL B. CHRISTENSEN ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Plasma Glucose ◽  
Systolic Function ◽  
Left Ventricular Systolic Function ◽  
Left Ventricular ◽  
Ventricular Systolic Function ◽  
Acute Changes

scholarly journals Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial

2020 ◽  
pp. 204748732093921 ◽  
Author(s):  
Giovanni Cioffi ◽  
Carlo Bruno Giorda ◽  
Donata Lucci ◽  
Elisa Nada ◽  
Federica Ognibeni ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Systolic Function ◽  
Left Ventricular Systolic Function ◽  
Left Ventricular ◽  
Left Ventricular Geometry ◽  
Ventricular Systolic Function ◽  
Diabetes Therapy ◽  
Ventricular Geometry ◽  
Fractional Shortening

Aims To evaluate the effect of linagliptin on left ventricular systolic function beyond glycaemic control in type 2 diabetes mellitus. Methods and results A multicentre, randomised, double-blind, placebo controlled, parallel-group study, was performed (the DYDA 2 trial). Individuals with type 2 diabetes mellitus and asymptomatic impaired left ventricular systolic function were randomly allocated in a 1:1 ratio to receive for 48 weeks either linagliptin 5 mg daily or placebo, in addition to their diabetes therapy. Eligibility criteria were age 40 years and older, haemoglobin A1c 8.0% or less (≤64 mmol/mol), no history of cardiac disease, concentric left ventricular geometry (relative wall thickness ≥0.42), impaired left ventricular systolic function defined as midwall fractional shortening 15% or less at baseline echocardiography. The primary end point was the modification of midwall fractional shortening over time. The main secondary objectives were changes in diastolic and/or in longitudinal left ventricular systolic function as measured by tissue Doppler echocardiography. One hundred and eighty-eight patients were enrolled, predominantly men with typical insulin-resistance comorbidities. At baseline, mean midwall fractional shortening was 13.3%±2.5. At final evaluation, 88 linagliptin patients and 86 placebo patients were compared: midwall fractional shortening increased from 13.29 to 13.82 (+4.1%) in the linagliptin group, from 13.58 to 13.84 in the placebo group (+1.8%, analysis of covariance P = 0.86), corresponding to a 2.3-fold higher increase in linagliptin than the placebo group, although non-statistically significant. Also, changes in diastolic and longitudinal left ventricular systolic function did not differ between the groups. Serious adverse events or linagliptin/placebo permanent discontinuation occurred in very few cases and in the same percentage between the groups. Conclusions In the DYDA 2 patients the addition of linagliptin to stable diabetes therapy was safe and provided a modest non-significant increase in left ventricular systolic function measured as midwall fractional shortening. Trial registration number: ClinicalTrial.gov (ID NCT02851745)

scholarly journals Enhanced left ventricular systolic function early in type 2 diabetic mice: clinical implications

2004 ◽  
Vol 1 (2) ◽  
pp. 89-94 ◽  
Author(s):  
Jorge A Alvarez ◽  
Maricela Reyes ◽  
Daniel Escobedo ◽  
Gregory L Freeman ◽  
Mark E Steinhelper ◽  
...  
Keyword(s):  
Systolic Function ◽  
Left Ventricular Systolic Function ◽  
Left Ventricular ◽  
Clinical Implications ◽  
Diabetic Mice ◽  
Ventricular Systolic Function ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document